



PRESS RELEASE¹

Three new R&D projects accredited by Lyonbiopole obtain public funding from the 8th Call for Projects of the Single Inter-Ministry Fund (FUI)

Lyon/Grenoble, September 8th, 2009 – Thanks to the accreditation of Lyonbiopole, worldwide competitiveness cluster, the NATHEB, EXPAND ID and PATVAX R&D projects will receive €6 million public funding (FUI).

Those three R&D projects, accredited by Lyonbiopole and submitted in 2009 in response to the 8th call for projects of FUI, benefit from public funding: the State (FUI) and also the European Regional Development Fund (EDFR), and regional authorities: the Rhône-Alpes Region, Greater Lyon, Grenoble Alpes Metropole.

1- NATHEB: new therapeutic approaches in the treatment of chronic Hepatitis B.

Partners:

- [EDELIRIS \(Lyon, France\) \(Project leader\)](#)
- TRANSGENE Département Maladies Infectieuses (Lyon, France)
- POXEL (Lyon, France)
- Inserm U851, Dr.Vincent Lotteau (Lyon, France)



The aim of the project is to develop a new efficient therapy against hepatitis B, which despite the efficacy of current vaccines, strikes over 350 million people in the world, and particularly in emerging countries. These new treatments will allow a better control over replication of the viral genome and viral antigen expression as well as a better stimulation of the host immune response.

¹ This press release was adapted to fit Edelris web site. To see the original from Lyon Biopole, see Press release: <http://www.lyonbiopole.com/images/874-1-08092009-press-release-version-finale-pdf.pdf>

2- EXPAND ID: extending the scope of application of intradermal vaccination.

Partners:

- BD (Grenoble, France) (project leader)
- Sanofi pasteur (Lyon, France)
- Inserm U851, Pr. Jean-François Nicolas (Lyon, France)

Based on the success of the intradermal vaccine against seasonal flu disease, the Lyonbiopole EXPAND ID project is aimed at expanding the field of applications for intradermal vaccination. The objectives are to define the injections parameters for other vaccines than flu, to precise the conditions necessary for application in the elderly through in depth analysis of the fundamental biological events occurring in immunosenescence, to develop a micro-injection device in order to offer a simple, safe and efficient delivery system for lyophilised vaccines.

3- PATVAX: development of innovative interaction measurement systems (micro-probes) within heterogenous biological environment for in line monitoring of bio- industrial processes.

Partners:

- Sanofi pasteur (Lyon, France) (project leader)
- CEA LETI (Grenoble, France)
- MERAL (Lyon, France)
- CYBERSTAR (Grenoble, France)
- Laboratoire de Physique ENS- Lyon - UMR5672 (Lyon, France)
- SmartINST (Lyon, France)

PATVAX challenge is to develop new in-line and real time measurement systems based on innovative probes introduced within manufacturing process. This innovative Process Analytical Technology will provide continuous analytical information to monitor and drive the process toward an optimal trajectory.

About Edelris: EDELRIIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELRIIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies have already recognized the value and specificity of the EDELRIIS offer, accessing either its experienced MedChem services or its innovative natural product-like Keymical Collections™.

EDELRIIS s.a.s.
Jean-Yves Ortholand, CEO
Phone: +33 (0) 437 561 901
jean-yves.ortholand@edelris.com